Wolfram Syndrome

Wolfram syndrome is a rare genetic condition that affects many different parts of the body. It is sometimes called DIDMOAD, which stands for the four most common problems it causes: Diabetes Insipidus (a condition that causes extreme thirst and frequent urination), Diabetes Mellitus (high blood sugar), Optic Atrophy (vision loss), and Deafness (hearing loss). The first sign of the condition is usually diabetes, which typically appears in childhood around age 6. This is followed by vision problems, usually starting around age 11. The vision loss in Wolfram syndrome is caused by damage to the optic nerve, which carries visual information from the eye to the brain. This damage, called optic atrophy, causes a gradual loss of vision, starting with difficulty seeing colors and losing side vision, and often progressing to severe vision loss or legal blindness over several years. As patients get older, they may also develop hearing loss, bladder problems, and difficulties with balance and coordination. Currently, there is no cure for Wolfram syndrome, and treatments focus on managing the symptoms to improve quality of life. This includes using insulin for diabetes, hearing aids for hearing loss, and medications for bladder issues. Regular check-ups with a team of doctors, including eye specialists, endocrinologists, and neurologists, are very important. Researchers are actively studying new treatments, including medications and gene therapies, to help slow down or stop the progression of the disease.

Condition category: Syndromic IRD

Prevalence: 1 in 500,000

Inheritance patterns: Autosomal Recessive

Age of onset: First decade of life (typically around age 6 for diabetes mellitus and age 11 for optic atrophy)

Clinical overview: Wolfram syndrome, historically known by the acronym DIDMOAD (Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, and Deafness), is a rare, progressive neurodegenerative and endocrine disorder. It is classified primarily into two types: Wolfram syndrome type 1 (WS1), caused by mutations in the WFS1 gene, and the much rarer Wolfram syndrome type 2 (WS2), caused by mutations in the CISD2 gene. The condition is characterized by the sequential development of juvenile-onset insulin-dependent diabetes mellitus and bilateral optic atrophy, which are the core diagnostic criteria. The clinical significance of Wolfram syndrome lies in its profound impact on multiple organ systems, leading to severe morbidity and premature mortality. Beyond the defining features of diabetes and vision loss, patients frequently suffer from central diabetes insipidus, sensorineural hearing loss, significant urological tract abnormalities, and progressive neurological decline, including ataxia and brainstem atrophy. Psychiatric manifestations, such as severe depression and anxiety, are also common as the disease progresses. Wolfram syndrome is recognized as a prototype endoplasmic reticulum (ER) disease, providing critical insights into the role of ER stress and calcium homeostasis in cellular survival, particularly in pancreatic beta-cells and neurons. The condition is cataloged under OMIM #222300 for WS1 and OMIM #604928 for WS2, with the Orphanet number ORPHA:3463. Despite its rarity, the study of Wolfram syndrome has broader implications for understanding more common disorders involving ER stress, such as type 1 and type 2 diabetes and other neurodegenerative diseases.

Patient and family guide: Wolfram syndrome is a rare genetic condition that affects many different parts of the body. It is sometimes called DIDMOAD, which stands for the four most common problems it causes: Diabetes Insipidus (a condition that causes extreme thirst and frequent urination), Diabetes Mellitus (high blood sugar), Optic Atrophy (vision loss), and Deafness (hearing loss). The first sign of the condition is usually diabetes, which typically appears in childhood around age 6. This is followed by vision problems, usually starting around age 11. The vision loss in Wolfram syndrome is caused by damage to the optic nerve, which carries visual information from the eye to the brain. This damage, called optic atrophy, causes a gradual loss of vision, starting with difficulty seeing colors and losing side vision, and often progressing to severe vision loss or legal blindness over several years. As patients get older, they may also develop hearing loss, bladder problems, and difficulties with balance and coordination. Currently, there is no cure for Wolfram syndrome, and treatments focus on managing the symptoms to improve quality of life. This includes using insulin for diabetes, hearing aids for hearing loss, and medications for bladder issues. Regular check-ups with a team of doctors, including eye specialists, endocrinologists, and neurologists, are very important. Researchers are actively studying new treatments, including medications and gene therapies, to help slow down or stop the progression of the disease.

Symptoms and clinical features: The clinical presentation of Wolfram syndrome is characterized by a sequential onset of symptoms that progressively involve multiple organ systems. In the early stage, typically during the first decade of life, the hallmark symptom is the onset of non-autoimmune, insulin-dependent diabetes mellitus. This is often the presenting feature, occurring at a median age of 6 years. Shortly after, usually in the early second decade (around age 11), patients develop optic atrophy. Initial visual symptoms include a loss of color vision and peripheral vision, which gradually progresses to a severe reduction in central visual acuity. During the intermediate stage, typically in the second and early third decades, additional endocrine and sensory deficits emerge. About 70% of patients develop central diabetes insipidus, presenting with polyuria and polydipsia. Sensorineural hearing loss also becomes apparent, initially affecting high frequencies and progressing slowly. Urological symptoms begin to manifest, including urinary urgency, incontinence, and recurrent urinary tract infections, driven by neurogenic bladder and structural abnormalities like hydroureteronephrosis. In the advanced stage, usually from the third decade onwards, progressive neurological and psychiatric symptoms dominate the clinical picture. Patients develop truncal ataxia, peripheral neuropathy, and bulbar dysfunction, leading to difficulties with balance, coordination, speech (dysarthria), and swallowing (dysphagia). Brainstem atrophy can cause central apnea and respiratory failure. Psychiatric manifestations, including severe depression, anxiety, and sometimes psychosis, become increasingly common. Endocrine issues may expand to include hypogonadism, leading to delayed puberty or infertility. The culmination of these multi-systemic failures leads to severe disability and premature mortality.

Molecular pathology: Wolfram syndrome is fundamentally a disorder of endoplasmic reticulum (ER) stress and calcium homeostasis. In Wolfram syndrome type 1, the causative gene, WFS1, encodes wolframin, a transmembrane glycoprotein primarily localized to the ER membrane. Wolframin is highly expressed in tissues with high secretory demands, such as pancreatic beta-cells, retinal ganglion cells, and neurons. Its normal function involves regulating ER calcium levels and managing the unfolded protein response (UPR). Mutations in WFS1 lead to a loss of wolframin function, resulting in the accumulation of misfolded proteins and disrupted calcium homeostasis within the ER. This chronic ER stress overwhelms the cell's adaptive mechanisms, triggering apoptosis. The death of pancreatic beta-cells leads to insulin-dependent diabetes mellitus, while the apoptosis of retinal ganglion cells results in progressive optic atrophy. The widespread expression of wolframin in the brain accounts for the diverse neurological and neuroendocrine manifestations of the disease. In Wolfram syndrome type 2, mutations in the CISD2 gene affect the ERIS (Endoplasmic Reticulum Intermembrane Small) protein, a zinc-finger protein localized to the mitochondria-associated ER membranes (MAMs). Like wolframin, ERIS plays a crucial role in maintaining ER calcium homeostasis and mitochondrial function. Loss of CISD2 function disrupts the interaction between the ER and mitochondria, leading to altered calcium signaling, mitochondrial dysfunction, and ultimately, cellular apoptosis. This shared pathway of ER stress and calcium dysregulation unites the divergent genetic causes of Wolfram syndrome.

Genetics: Wolfram syndrome is primarily inherited in an autosomal recessive manner. The classic and most common form, Wolfram syndrome type 1 (WS1), is caused by homozygous or compound heterozygous mutations in the WFS1 gene, located on chromosome 4p16.1. The WFS1 gene encodes the protein wolframin. A wide variety of mutations have been identified, including missense, nonsense, frameshift, and splice-site mutations, with most occurring in exon 8. Inactivating mutations are generally associated with an earlier onset and a more severe disease course compared to missense mutations. A rarer form, Wolfram syndrome type 2 (WS2), is caused by mutations in the CISD2 gene, located on chromosome 4q24. WS2 shares many clinical features with WS1, such as diabetes mellitus and optic atrophy, but is typically characterized by the absence of diabetes insipidus and the presence of bleeding tendencies due to defective platelet aggregation, as well as upper intestinal ulcers. While classic Wolfram syndrome is autosomal recessive, heterozygous dominant mutations in the WFS1 gene can cause Wolfram-like syndrome. This condition is characterized by a milder phenotype, often presenting with isolated adult-onset diabetes, progressive low-frequency sensorineural hearing loss, or isolated optic atrophy, without the severe progressive neurodegeneration seen in the classic recessive form. Additionally, some patients with Wolfram syndrome have been found to have concomitant mutations in mitochondrial DNA, suggesting a complex interplay between nuclear and mitochondrial genetics that may influence disease severity.

Diagnostic evaluation: The diagnosis of Wolfram syndrome is primarily based on the concurrent presence of juvenile-onset diabetes mellitus and optic atrophy. Clinical workup includes a comprehensive ophthalmologic examination. Fundoscopy typically reveals a pale optic disc indicative of optic atrophy. Optical coherence tomography (OCT) shows progressive thinning of the retinal nerve fibre layer and the macular ganglion cell layer, and sometimes a characteristic lamination pattern at the outer plexiform layer. Visual field testing often reveals central scotomas and a generalized reduction in retinal sensitivity. Electroretinography (ERG) results are typically normal, consistent with optic atrophy due to retinal ganglion cell axon loss rather than primary photoreceptor degeneration, while visual evoked potentials (VEP) show delayed latencies and reduced amplitudes. Systemic evaluation is crucial and includes endocrine assessments for diabetes mellitus and diabetes insipidus, audiometry to detect high-frequency sensorineural hearing loss, and renal ultrasound to identify structural abnormalities like hydroureteronephrosis or a neurogenic bladder. Neurological assessments, including brain MRI, may show generalized brain atrophy, particularly of the brainstem, cerebellum, and optic nerves. Confirmation of the diagnosis is achieved through molecular genetic testing. Sanger sequencing or next-generation sequencing panels targeting the WFS1 and CISD2 genes are the gold standard. Differential diagnosis includes mitochondrial disorders (such as Leber Hereditary Optic Neuropathy or MELAS), autosomal dominant optic atrophy, Friedreich ataxia, Bardet-Biedl syndrome, and Alström syndrome. Distinguishing Wolfram syndrome from these conditions relies on the specific combination of clinical features and genetic confirmation.

Differential diagnosis: Differential diagnosis of Wolfram syndrome includes: (1) Type 1 diabetes mellitus (isolated) — no optic atrophy or other Wolfram features. (2) Autosomal dominant optic atrophy (Kjer disease) — OPA1 mutations, no diabetes or hearing loss. (3) Leber hereditary optic neuropathy — mitochondrial, acute/subacute onset, male predominance. (4) Friedreich ataxia — optic atrophy with ataxia and cardiomyopathy but no diabetes insipidus. (5) Mitochondrial disorders (MELAS, MERRF) — variable optic atrophy with other neurological features. (6) Thiamine-responsive megaloblastic anemia syndrome — diabetes, hearing loss, megaloblastic anemia; SLC19A2 mutations.

Natural history: The natural history of Wolfram syndrome is characterized by a progressive, sequential onset of clinical features. Diabetes mellitus is typically the first manifestation, presenting in the first decade of life at a median age of 6 years. This is followed by the development of optic atrophy in the early second decade, with a median age of onset around 11 years. Optic atrophy leads to a gradual and severe decline in visual acuity, with most patients progressing to legal blindness (20/200 vision or worse) within 8 years of onset. During the second decade, patients often develop central diabetes insipidus (median age 15.5 years) and sensorineural hearing loss. The hearing loss is typically high-frequency and slowly progressive. In the third decade, urological abnormalities, such as neurogenic bladder and hydroureteronephrosis, and neurological manifestations, including truncal ataxia, peripheral neuropathy, and bulbar dysfunction, become prominent. The disease is relentlessly progressive, leading to severe neurodegeneration. The prognosis is generally poor, with significant morbidity from neurological and urological complications. The median age of death is historically reported to be around 30 to 40 years, often due to central respiratory failure secondary to brainstem atrophy, or end-stage renal disease from recurrent urinary tract infections. However, with improved supportive care, some patients are living into their fifth and sixth decades.

Management and treatment research: ### Current Management and Standard of Care There is currently no cure for Wolfram syndrome. Care focuses on treating individual symptoms, monitoring for complications, and coordinating care among specialists. Depending on a person’s needs, the care team may include endocrinologists, ophthalmologists, audiologists, urologists, neurologists, mental-health professionals, and rehabilitation providers. - **Diabetes mellitus:** Most people require insulin therapy. Insulin needs may differ from those in autoimmune type 1 diabetes, so treatment should be individualized with regular glucose monitoring. - **Central diabetes insipidus:** This condition causes excessive thirst and urination because the body does not make enough antidiuretic hormone. It is commonly treated with desmopressin, with careful monitoring of fluid intake and electrolyte balance. - **Vision loss from optic atrophy:** Low-vision services, assistive technology, orientation and mobility training, and school or workplace accommodations can support independence. - **Hearing loss:** Hearing aids, communication support, and cochlear implant evaluation when appropriate may be helpful. - **Bladder and urinary tract problems:** Neurogenic bladder dysfunction can increase the risk of urinary infections and kidney damage. Management may include timed voiding, medicines that relax the bladder, clean intermittent catheterization, and prompt treatment of infections. - **Neurologic, mobility, swallowing, and mental-health symptoms:** Physical, occupational, and speech therapy, along with neurologic and mental-health care, can address individual needs. ### Approved Therapies There are no therapies approved specifically to slow, stop, or reverse Wolfram syndrome. Available treatments manage diabetes, diabetes insipidus, hearing loss, bladder dysfunction, vision-related disability, and other complications. ### Investigational Therapies #### Pharmacological therapy - **AMX0035:** A Phase 2 study of AMX0035 in adults with Wolfram syndrome is active but not recruiting (**NCT05676034**). AMX0035 combines sodium phenylbutyrate and taurursodiol. The study is evaluating safety and possible effects on features of Wolfram syndrome. AMX0035 is investigational for Wolfram syndrome and is not an approved treatment for this condition. #### Gene-based research Wolfram syndrome is most often caused by disease-causing changes in the **WFS1** gene. Research is exploring how WFS1-related changes affect cell function, including stress in the endoplasmic reticulum (ER), a cell structure involved in protein processing and calcium regulation. There are no gene therapy or gene-editing treatment trials for Wolfram syndrome in the current clinical-trial data. ### Clinical Trial Participation Clinical studies may include treatment trials, natural-history studies, registries, and research focused on diagnosis or specific symptoms. - The **Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study** is recruiting (**NCT02841553**). - A study of **monogenic diabetes misdiagnosed as type 1 diabetes** is recruiting (**NCT03988764**). - Studies examining WFS1-related optic atrophy and Wolfram-like syndromes are active but not recruiting or not yet recruiting (**NCT07485413**, **NCT07336966**). - A study of the **mechanisms of fecal incontinence in Wolfram syndrome** is not yet recruiting (**NCT07313085**). Eligibility, locations, and recruitment status can change. A Wolfram syndrome specialist or care team can help individuals and families discuss whether a study may be appropriate.

Outlook: The prognosis for individuals with classic Wolfram syndrome is generally poor due to the progressive nature of the neurodegeneration. Visual outcomes are typically severe, with most patients progressing to legal blindness within a decade of the onset of optic atrophy. The progressive neurological decline, including ataxia, bulbar dysfunction, and brainstem atrophy, significantly impacts mobility, swallowing, and respiratory function. Quality of life is profoundly affected by the combination of vision and hearing loss, complex medical management of diabetes and urological issues, and the development of psychiatric symptoms such as depression and anxiety. Historically, the median age of death has been reported in the 30s, often due to respiratory failure from brainstem involvement or renal failure from recurrent urinary tract infections. However, with proactive, multidisciplinary medical care and careful management of complications, life expectancy can be extended, and some patients live into their 50s and 60s.

Epidemiology: Wolfram syndrome is a rare genetic disorder with an estimated prevalence ranging from 1 in 100,000 in North America to 1 in 770,000 in the United Kingdom. The prevalence in children has been reported as approximately 1 in 500,000 worldwide. The carrier frequency of WFS1 mutations is estimated to be as high as 1% in the general population. The incidence of the disease is higher in populations with greater rates of consanguinity, such as certain Middle Eastern communities. There are no significant sex differences in the overall prevalence of the disease, although specific manifestations, such as hypogonadism, may be more prevalent or present differently in males compared to females.

Selected references: 1. Barrett TG, Bundey SE, Macleod AF. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet. 1995;346(8988):1458-1463. PMID: 7490992 2. Urano F. Wolfram Syndrome: Diagnosis, Management, and Treatment. Curr Diab Rep. 2016;16(1):6. PMID: 26742731 3. Abreu D, Urano F. Current landscape of treatments for Wolfram syndrome. Trends Pharmacol Sci. 2019;40(10):711-714. PMID: 31474358 4. Rouzier C, Moore D, Delorme C, et al. A novel CISD2 mutation associated with a classical Wolfram syndrome phenotype alters Ca2+ homeostasis and ER-mitochondria interactions. Hum Mol Genet. 2017;26(9):1599-1611. PMID: 28334880 5. Delprat B, Maurice T, Delettre C. Wolfram syndrome: MAMs' connection? Cell Death Dis. 2018;9(3):364. PMID: 29511175 6. Rigoli L, Lombardo F, Di Bella C. Genetic and clinical aspects of Wolfram syndrome 1, a severe neurodegenerative disease. Pediatr Res. 2018;83(5):921-929. PMID: 29489725 7. de Heredia ML, Cleries R, Nunes V. Genotypic classification of patients with Wolfram syndrome: insights into the natural history of the disease and correlation with phenotype. Genet Med. 2013;15(7):497-506. PMID: 23412609